India’s Sun Pharma is considering establishing a production plant in Russia for Ranbaxy, the pharmaceutical company it is currently in the process of acquiring. The plant, which could require up to $200m in investment, would focus on proprietary Ranbaxy antibiotic and analgesic brands and possibly also drugs for the treatment of diseases related to gastroenterology, cardiovascular and metabolism. Invest in Russia